For the first time today, Eli Lilly and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance’s investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus®)